記住我
Courand PY, Dinic M, Lorthioir A, et al. Resistant hypertension and atherosclerotic renal artery stenosis: effects of angioplasty on ambulatory blood pressure. a retrospective uncontrolled single-center study. Hypertension 2019; 74: 1516−1523.
[16] [17] Laurent S, Boutouyrie P. Arterial stiffness and hypertension in the elderly. Front Cardiovasc Med 2020; 7: 544302. doi: 10.3389/fcvm.2020.544302 [18] Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318−1327. doi: 10.1016/j.jacc.2009.10.061 [19] Gosse P, Jan E, Coulon P, et al. ECG detection of left ventricular hypertrophy: the simpler, the better? J Hypertens 2012; 30: 990−996. doi: 10.1097/HJH.0b013e3283524961 [20] Courand PY, Jenck S, Bricca G, et al. R wave in aVL lead: an outstanding ECG index in hypertension. J Hypertens 2014; 32: 1317−1325. doi: 10.1097/HJH.0000000000000181 [21] Verdecchia P, Angeli F, Cavallini C, et al. The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. J Hypertens 2009; 27: 1697−1704. doi: 10.1097/HJH.0b013e32832c0031 [22] Jain A, Tandri H, Dalal D, et al. Diagnostic and prognostic utility of electrocardiography for left ventricular hypertrophy defined by magnetic resonance imaging in relationship to ethnicity: The Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2010; 159: 652−658. doi: 10.1016/j.ahj.2009.12.035 [23] Courand PY, Gaudebout N, Mouly-Bertin C, et al. Biological, electrical and echocardiographic indices versus cardiac magnetic resonance imaging in diagnosing left ventricular hypertrophy. Hypertens Res 2014; 37: 444−451. doi: 10.1038/hr.2013.147 [24] Aro AL, Chugh SS. Clinical diagnosis of electrical versus anatomic left ventricular hypertrophy: prognostic and therapeutic implications. Circ Arrhythm Electrophysiol 2016; 9: e003629. doi: 10.1161/CIRCEP.115.003629 [25]Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 2014; 35: 1245–1254.
[26] Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371: 1921−1926. doi: 10.1016/S0140-6736(08)60834-X [27]Takeda M, Yamamoto K, Akasaka H, et al. Clinical characteristics and postoperative outcomes of primary aldosteronism in the elderly. J Clin Endocrinol Metab 2018; 103: 3620–3629.
[28] Eschalier R, McMurray JJV, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013; 62: 1585−1593. doi: 10.1016/j.jacc.2013.04.086 [29] ASTRAL Investigators, Wheatley K, Ives N, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009; 361: 1953−1962. doi: 10.1056/NEJMoa0905368 [30]Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2017; 370: 13−22.
[31]
留言 (0)